Fospropofol approved for monitored anesthesia care

FDA in mid-December approved the marketing of fospropofol disodium injection, or Lusedra, as an agent for providing monitored anesthesia care sedation in adults undergoing diagnostic or therapeutic procedures. The drug is a water-soluble prodrug of the sedative–hypnotic agent propofol, which is